Login / Signup

Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials.

Yasuhiko MatsumoriMiki IshidaKatsuhiro IbaByung-Kun KimXiaoping NingMasami NakaiNobuyuki Koga
Published in: Headache (2023)
Patients with EM/CM receiving monthly or quarterly fremanezumab, for a duration of 12 weeks, showed significant improvements in their QoL.
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • phase ii
  • phase iii
  • phase ii study
  • study protocol
  • open label
  • gestational age
  • radiation therapy
  • locally advanced